Enantema quale prima manifestazione clinica della reazione di ipersensibilità da abacavir: Descrizione di un caso clinico

Translated title of the contribution: Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: A case report

Massimiliano Lanzafame, Marco Trevenzoli, Emanuela Lattuada, Federica Faggian, Sandro Vento, Ercole Concia

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in combination with other antiretroviral drugs for the treatment of HIV 1-infection. Approximately 3% of patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir.

Translated title of the contributionEnanthema as the first clinical manifestation of abacavir hypersensitivity reaction: A case report
Original languageItalian
Pages (from-to)40-41
Number of pages2
JournalInfezioni in Medicina
Volume11
Issue number1
Publication statusPublished - Apr 30 2003

Keywords

  • Abacavir
  • Enantema
  • Ipersensibilità

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: A case report'. Together they form a unique fingerprint.

Cite this